CDKN2A and non-small cell lung carcinoma: In a systematic review of 72 studies comprising data from 2346 patients, the most common genetic alterations seen in BMs from NSCLC were EGFR, TP53, KRAS (Kirsten rat sarcoma viral oncogene), CDKN2A (cyclin-dependent kinase inhibitor 2A), and STK11 [52].